Details of Disease

General Information of Disease (ID: DISSXFCF)

Disease Name Relapsing-remitting multiple sclerosis
Synonyms RRMS; Relapsing-remitting MS
Disease Class 8A40: Multiple sclerosis
Definition
The most common clinical variant of multiple sclerosis, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see optic neuritis), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)
Disease Hierarchy
DISB2WZI: Multiple sclerosis
DISSXFCF: Relapsing-remitting multiple sclerosis
ICD Code
ICD-11
ICD-11: 8A40.0
Expand ICD-11
'8A40.0
Disease Identifiers
MONDO ID
MONDO_0005314
MESH ID
D020529
UMLS CUI
C0751967
MedGen ID
155669
SNOMED CT ID
426373005

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 1 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Cladribine DM3JDRP Approved Small molecular drug [1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 17 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
APOE TTKS9CB moderate Genetic Variation [2]
CD52 TTQT5S9 Strong Biomarker [3]
IL12RB2 TT4SWR8 Strong Altered Expression [4]
IL31 TT1RJXK Strong Altered Expression [5]
LAMC2 TTNS7H3 Strong Biomarker [6]
LRRC32 TT0FAYT Strong Altered Expression [7]
MBP TT2RY5P Strong Genetic Variation [8]
MBTPS1 TTNSM2I Strong Biomarker [9]
PLD1 TT3T17P Strong Altered Expression [10]
RTN4R TTVRZUO Strong Biomarker [11]
S1PR1 TT9JZCK Strong Biomarker [12]
TLR7 TTRJ1K4 Strong Biomarker [13]
UBC TTBP3XA Strong Altered Expression [14]
IL11 TTGUYTR Definitive Biomarker [15]
IL12B TTGW72V Definitive Genetic Variation [16]
ITGA4 TTJMF9P Definitive Biomarker [17]
MOG TTQAFX5 Definitive Biomarker [18]
------------------------------------------------------------------------------------
⏷ Show the Full List of 17 DTT(s)
This Disease Is Related to 1 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
TGM6 DEUWCVD Strong Altered Expression [19]
------------------------------------------------------------------------------------
This Disease Is Related to 27 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
NOX3 OT0FFJH8 moderate Genetic Variation [20]
AADAC OT8VACT2 Strong Biomarker [21]
BMP5 OTC0Y6E0 Strong Altered Expression [22]
CARD16 OT4NUHWB Strong Biomarker [23]
CCL26 OT2B7HR9 Strong Altered Expression [24]
CHI3L1 OT2Z7VJH Strong Biomarker [25]
CNGB1 OTA5DE38 Strong Altered Expression [7]
COP1 OT6J2K12 Strong Biomarker [23]
DGCR8 OT62LXE4 Strong Altered Expression [26]
ERMN OTS3PBOH Strong Altered Expression [27]
FBXW4 OTEGSZOX Strong Biomarker [21]
HINT2 OTW9GS0U Strong Biomarker [28]
IFNA1 OTPMKY0L Strong Biomarker [29]
ISG20 OTCWRJJW Strong Biomarker [30]
NEFL OTQESJV4 Strong Biomarker [31]
NKRF OTUVY0P6 Strong Altered Expression [32]
NLRC4 OTAIA3NA Strong Biomarker [33]
PHEX OTG7N3J7 Strong Biomarker [21]
PIAS3 OT3TWH9R Strong Altered Expression [32]
PLP1 OT8CM9CX Strong Biomarker [34]
PRCC OTJ0KRYX Strong Biomarker [35]
RO60 OTLGM5A8 Strong Biomarker [36]
RRN3 OTKGOZ49 Strong Altered Expression [37]
SPG11 OTZ7LJX4 Strong Genetic Variation [38]
SPINK7 OTK3VOI3 Strong Genetic Variation [39]
SPNS2 OTPODAPU Strong Biomarker [12]
TOR2A OT1EGCDU Strong Altered Expression [40]
------------------------------------------------------------------------------------
⏷ Show the Full List of 27 DOT(s)

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 APOE-epsilon4 is not associated with cognitive impairment in relapsing-remitting multiple sclerosis.Mult Scler. 2009 Dec;15(12):1489-94. doi: 10.1177/1352458509348512. Epub 2009 Nov 13.
3 Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis.Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738419843690. doi: 10.1177/2058738419843690.
4 Higher expression of IL-12R2 is associated with lower risk of relapse in relapsing-remitting multiple sclerosis patients on interferon-1b therapy during 3-year follow-up.J Neuroimmunol. 2015 Oct 15;287:64-70. doi: 10.1016/j.jneuroim.2015.07.011. Epub 2015 Aug 12.
5 Decreased serum levels of sCD40L and IL-31 correlate in treated patients with Relapsing-Remitting Multiple Sclerosis.Immunobiology. 2018 Jan;223(1):135-141. doi: 10.1016/j.imbio.2017.10.001. Epub 2017 Oct 5.
6 Dimethyl fumarate therapy reduces memory T cells and the CNS migration potential in patients with multiple sclerosis.Mult Scler Relat Disord. 2020 Jan;37:101451. doi: 10.1016/j.msard.2019.101451. Epub 2019 Oct 16.
7 Promising effect of rapamycin on multiple sclerosis.Mult Scler Relat Disord. 2018 Nov;26:40-45. doi: 10.1016/j.msard.2018.08.009. Epub 2018 Aug 10.
8 In Vitro Effects of Sodium Benzoate on Th1/Th2 Deviation in Patients with Multiple Sclerosis.Immunol Invest. 2016 Oct;45(7):679-91. doi: 10.1080/08820139.2016.1208216. Epub 2016 Sep 9.
9 Possible regenerative effects of fingolimod (FTY720) in multiple sclerosis disease: An overview on remyelination process.J Neurosci Res. 2020 Mar;98(3):524-536. doi: 10.1002/jnr.24509. Epub 2019 Aug 5.
10 Phospholipase D1 expression analysis in relapsing-remitting multiple sclerosis patients.Neurol Sci. 2017 May;38(5):865-872. doi: 10.1007/s10072-017-2857-1. Epub 2017 Feb 22.
11 In-Depth Cerebrospinal Fluid Quantitative Proteome and Deglycoproteome Analysis: Presenting a Comprehensive Picture of Pathways and Processes Affected by Multiple Sclerosis.J Proteome Res. 2017 Jan 6;16(1):179-194. doi: 10.1021/acs.jproteome.6b00659. Epub 2016 Oct 26.
12 Lipid transporter Spns2 promotes microglia pro-inflammatory activation in response to amyloid-beta peptide.Glia. 2019 Mar;67(3):498-511. doi: 10.1002/glia.23558. Epub 2018 Nov 28.
13 Thymosin-1 expands deficient IL-10-producing regulatory B cell subsets in relapsing-remitting multiple sclerosis patients.Mult Scler. 2018 Feb;24(2):127-139. doi: 10.1177/1352458517695892. Epub 2017 Feb 1.
14 Identification of Suitable Reference Genes for Peripheral Blood Mononuclear Cell Subset Studies in Multiple Sclerosis.Scand J Immunol. 2016 Jan;83(1):72-80. doi: 10.1111/sji.12391.
15 IL-11 Induces Encephalitogenic Th17 Cells in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.J Immunol. 2019 Sep 1;203(5):1142-1150. doi: 10.4049/jimmunol.1900311. Epub 2019 Jul 24.
16 IL12B gene polymorphisms have sex-specific effects in relapsing-remitting multiple sclerosis.Acta Neurol Belg. 2019 Mar;119(1):83-93. doi: 10.1007/s13760-018-01066-3. Epub 2018 Dec 15.
17 In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma.Immunol Lett. 2017 Jan;181:109-115. doi: 10.1016/j.imlet.2016.11.015. Epub 2016 Dec 2.
18 Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease.J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):132-136. doi: 10.1136/jnnp-2016-314005. Epub 2016 Oct 8.
19 Transglutaminase-6 is an autoantigen in progressive multiple sclerosis and is upregulated in reactive astrocytes.Mult Scler. 2017 Nov;23(13):1707-1715. doi: 10.1177/1352458516684022. Epub 2016 Dec 22.
20 Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes.Nat Commun. 2019 Jul 12;10(1):3081. doi: 10.1038/s41467-019-11139-3.
21 Daclizumab and its use in multiple sclerosis treatment.Drugs Today (Barc). 2017 Jan;53(1):7-18. doi: 10.1358/dot.2017.53.1.2570979.
22 High serum levels of BMP-2 correlate with BMP-4 and BMP-5 levels and induce reduced neuronal phenotype in patients with relapsing-remitting multiple sclerosis.J Neuroimmunol. 2017 Sep 15;310:120-128. doi: 10.1016/j.jneuroim.2017.07.008. Epub 2017 Jul 15.
23 Glatiramer Acetate: from Bench to Bed and Back.Isr Med Assoc J. 2019 Mar;21(3):151-157.
24 CCL26 and CCR3 are associated with the acute inflammatory response in the CNS in experimental autoimmune encephalomyelitis.J Neuroimmunol. 2019 Aug 15;333:576967. doi: 10.1016/j.jneuroim.2019.576967. Epub 2019 May 16.
25 Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis.Mult Scler. 2019 Oct;25(11):1444-1451. doi: 10.1177/1352458518794308. Epub 2018 Aug 16.
26 Overexpression of microRNA biogenesis machinery: Drosha, DGCR8 and Dicer in multiple sclerosis patients.J Clin Neurosci. 2015 Jan;22(1):200-3. doi: 10.1016/j.jocn.2014.06.106. Epub 2014 Oct 30.
27 Down-regulation of ERMN expression in relapsing remitting multiple sclerosis.Metab Brain Dis. 2019 Oct;34(5):1261-1266. doi: 10.1007/s11011-019-00429-w. Epub 2019 May 23.
28 Safety and efficacy of helminth treatment in relapsing-remitting multiple sclerosis: Results of the HINT 2 clinical trial.Mult Scler. 2019 Jan;25(1):81-91. doi: 10.1177/1352458517736377. Epub 2017 Oct 24.
29 Endogenous double-stranded Alu RNA elements stimulate IFN-responses in relapsing remitting multiple sclerosis.J Autoimmun. 2019 Jun;100:40-51. doi: 10.1016/j.jaut.2019.02.003. Epub 2019 Feb 28.
30 Rash developing after cessation of Daclizumab for relapsing remitting MS; a case series.Mult Scler Relat Disord. 2019 Oct;35:239-240. doi: 10.1016/j.msard.2019.08.008. Epub 2019 Aug 5.
31 Vitamin D(3) supplementation and neurofilament light chain in multiple sclerosis.Acta Neurol Scand. 2020 Jan;141(1):77-80. doi: 10.1111/ane.13185. Epub 2019 Nov 26.
32 Increased expression of mir-301a in PBMCs of patients with relapsing-remitting multiple sclerosis is associated with reduced NKRF and PIAS3 expression levels and disease activity.J Neuroimmunol. 2018 Dec 15;325:79-86. doi: 10.1016/j.jneuroim.2018.10.002. Epub 2018 Oct 4.
33 NLRP3 inflammasome is associated with the response to IFN- in patients with multiple sclerosis.Brain. 2015 Mar;138(Pt 3):644-52. doi: 10.1093/brain/awu388. Epub 2015 Jan 12.
34 Leptin increase in multiple sclerosis associates with reduced number of CD4(+)CD25+ regulatory T cells.Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5150-5. doi: 10.1073/pnas.0408995102. Epub 2005 Mar 23.
35 A computational approach based on the colored Petri net formalism for studying multiple sclerosis.BMC Bioinformatics. 2019 Dec 10;20(Suppl 6):623. doi: 10.1186/s12859-019-3196-4.
36 Defective structural RNA processing in relapsing-remitting multiple sclerosis.Genome Biol. 2015 Mar 25;16(1):58. doi: 10.1186/s13059-015-0629-x.
37 Suppressed RNA-polymerase 1 pathway is associated with benign multiple sclerosis.PLoS One. 2012;7(10):e46871. doi: 10.1371/journal.pone.0046871. Epub 2012 Oct 12.
38 A rare case of SPG11 mutation with multiple sclerosis.Rev Neurol (Paris). 2016 Jun-Jul;172(6-7):389-91. doi: 10.1016/j.neurol.2016.03.006. Epub 2016 May 11.
39 The impact of multiple sclerosis onset symptom on cardiac repolarization.Brain Behav. 2017 Jun 5;7(7):e00742. doi: 10.1002/brb3.742. eCollection 2017 Jul.
40 Increased level of plasma salusin- and salusin- in patients with multiple sclerosis.Mult Scler Relat Disord. 2019 May;30:76-80. doi: 10.1016/j.msard.2019.02.003. Epub 2019 Feb 5.